
Medtech giant Boston Scientific has had the wind in its sails during the second quarter of 2021.
In Q2, it delivered a USD 3.08bn revenue, up against the predicted USD 2.94bn, and it had a 52.4 percent organic growth compared to the same time period last year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app